PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.03%
Revenue growth at 50-75% of AVGO's 7.68%. Martin Whitman would worry about competitiveness or product relevance.
191.95%
Gross profit growth above 1.5x AVGO's 8.00%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
159.23%
EBIT growth above 1.5x AVGO's 5.07%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
159.23%
Operating income growth above 1.5x AVGO's 5.07%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
160.20%
Net income growth above 1.5x AVGO's 6.67%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
161.29%
EPS growth above 1.5x AVGO's 7.27%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
161.29%
Diluted EPS growth above 1.5x AVGO's 5.56%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.80%
Share count expansion well above AVGO's 0.41%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.73%
Diluted share count expanding well above AVGO's 0.40%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
517.80%
Positive OCF growth while AVGO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
5868.30%
Positive FCF growth while AVGO is negative. John Neff would see a strong competitive edge in net cash generation.
191.98%
10Y revenue/share CAGR above 1.5x AVGO's 19.49%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
27.81%
5Y revenue/share CAGR 1.25-1.5x AVGO's 19.49%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
-27.28%
Negative 3Y CAGR while AVGO stands at 19.49%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
722.75%
10Y OCF/share CAGR above 1.5x AVGO's 208.82%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
122.93%
5Y OCF/share CAGR at 50-75% of AVGO's 208.82%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-46.34%
Negative 3Y OCF/share CAGR while AVGO stands at 208.82%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
107.29%
Net income/share CAGR at 50-75% of AVGO's 184.70%. Martin Whitman might question if the firm’s product or cost base lags behind.
14.91%
Below 50% of AVGO's 184.70%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-65.38%
Negative 3Y CAGR while AVGO is 184.70%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
449.65%
Equity/share CAGR of 449.65% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
89.75%
Equity/share CAGR of 89.75% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
12.42%
Equity/share CAGR of 12.42% while AVGO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.90%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-12.99%
Inventory is declining while AVGO stands at 3.09%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
4.94%
Asset growth 1.25-1.5x AVGO's 4.41%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
4.15%
Similar to AVGO's 3.99%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-1.58%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-2.90%
Our R&D shrinks while AVGO invests at 11.84%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.29%
We cut SG&A while AVGO invests at 9.09%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.